Next-Generation Sequencing
ESMO Oncologists Debate Optimal Timing for Broad NGS, Align on Key Barriers to Precision Oncology
Premium
Oncologists argued for and against comprehensive NGS at the point of diagnosis but agreed on the need to address quality and cost barriers first.
ESMO Data in HER2-Positive Lung, Breast Cancer Bolster Daiichi Sankyo, AstraZeneca's Enhertu
Premium
Studies showed that the antibody-drug conjugate benefited HER2-mutated NSCLC patients and outperformed Genentech's T-DM1 in HER2-positive, previously treated breast cancer.
Two studies at the ESMO Congress highlighted unequal access to genetic testing for cancer patients and gaps in country-specific breast cancer risk guidelines in Europe.
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
The company said the results highlight precision oncology implementation challenges and its test's ability to help overcome these issues.